Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director · Interim CEO | August 18, 2023 | August 22, 2023 |
| Nuvectra CorpNVTR · Entity 152882 | Director | December 21, 2019 | December 26, 2019 |
| Sonendo, Inc.SONX · Entity 9738 | Director | September 17, 2024 | September 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date August 18, 2023 · Filed August 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 138,290 |
Reported balance
After 2023-08-18 transaction · row 1
1 source rowRow 1 · 2023-08-18 · Purchase · Acquired 13,290 · Balance 138,290 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.89 to $4.405, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Spouse's Trust | 26,595 |
Reported balance
After 2023-08-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-08-18 · Purchase · Acquired 26,595 · Balance 26,595 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.89 to $4.405, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2: Reflects shares directly held by The Irene A. Bihl Revocable Trust of which the Reporting Person and his spouse are trustees and among the beneficiaries. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.89 to $4.405, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2: Reflects shares directly held by The Irene A. Bihl Revocable Trust of which the Reporting Person and his spouse are trustees and among the beneficiaries. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Nuvectra Corp
Report date December 21, 2019 · Filed December 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,394 |
Reported balance
After 2019-12-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-12-21 · Exercise / conversion · Acquired 968 · Balance 30,394 F1: Vesting of Restricted Stock Units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-21 | Direct | 968 |
Reported balance
After 2019-12-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-21 · Exercise / conversion · Disposed 968 · Balance 968 F1: Vesting of Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting of Restricted Stock Units.
Sonendo, Inc.
Report date September 17, 2024 · Filed September 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 325,998 |
Reported balance
After 2024-09-17 transaction · row 1
1 source rowRow 1 · 2024-09-17 · Grant · Acquired 200,000 · Balance 325,998 F1: Represents an award of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2024 (the "Grant Date"). Each RSU represents a contingent right to receive one share of common stock, par value $0.001 per share of Sonendo, Inc. (the "Issuer"). The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2024 (the "Grant Date"). Each RSU represents a contingent right to receive one share of common stock, par value $0.001 per share of Sonendo, Inc. (the "Issuer"). The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MERIDIAN BIOSCIENCE INC
Report date January 31, 2023 · Filed January 31, 2023
Section 16 reporting ended · disclosed 2023-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 1
1 source rowRow 1 · 2023-01-31 · Disposition to issuer · Disposed 15,408 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.50 · Expires 2030-07-28 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-31 · Disposition to issuer · Disposed 4,595 · Balance 0 F2: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.36 · Expires 2031-01-27 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-31 · Disposition to issuer · Disposed 5,796 · Balance 0 F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.75 · Expires 2032-01-26 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-31 · Disposition to issuer · Disposed 5,656 · Balance 0 F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F2: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2024 Filed Sep 19, 2024 17:35 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-108197 · ownership.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,998 F1 · kind: Represents an award of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2024 (the "Grant Date"). Each RSU represents a contingent right to receive one share of common stock, par value $0.001 per share of Sonendo, Inc. (the "Issuer"). The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 22:20 UTC | Bioventus Inc. BVS · Entity 4996 | PurchaseClass A Common Stock | 26,595 | $4.14 | $110,071.39 |
DisclosureSEC source: 0001578563-23-000073 · primary_doc.xml · nonDerivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse's Trust Disclosed balance after: 26,595 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.89 to $4.405, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Reflects shares directly held by The Irene A. Bihl Revocable Trust of which the Reporting Person and his spouse are trustees and among the beneficiaries. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 22:20 UTC | Bioventus Inc. BVS · Entity 4996 | PurchaseClass A Common Stock | 13,290 | $4.14 | $55,004.65 |
DisclosureSEC source: 0001578563-23-000073 · primary_doc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,290 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.89 to $4.405, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:04 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantStock Option (Right to Buy) · Derivative | 32,520 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001562180-23-005395 · primarydocument.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,520 Underlying: Common Stock · 32,520 shares Expires 2033-06-15 F2 · derivative.exercise_date: The Options vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date and (ii) the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:04 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantCommon Stock | 25,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005395 · primarydocument.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,998 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| May 23, 2023 Filed May 25, 2023 01:17 UTC | Bioventus Inc. BVS · Entity 4996 | PurchaseClass A Common Stock | 125,000 | $2.33 | $290,987.50 |
DisclosureSEC source: 0001578563-23-000034 · primary_doc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $2.25 to $2.43, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 10, 2023 Filed Apr 13, 2023 00:26 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 198,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001578563-23-000018 · primary_doc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,000 Underlying: Class A Common Stock · 198,000 shares Expires 2033-04-10 F2 · derivative.exercise_date: The RSUs and options, as applicable, vest on April 10, 2024. Read SEC document |
| April 10, 2023 Filed Apr 13, 2023 00:26 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 76,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000018 · primary_doc.xml · derivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,000 Underlying: Class A Common Stock · 76,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs and options, as applicable, vest on April 10, 2024. F2 · derivative.expiration_date: The RSUs and options, as applicable, vest on April 10, 2024. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:16 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,656 | $13.25 Strike: $20.75 | $74,942.00 |
DisclosureSEC source: 0001567619-23-001532 · doc1.xml · derivative · entry 4 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,656 shares Expires 2032-01-26 F4 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F4 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F4 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:16 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,796 | $12.64 Strike: $21.36 | $73,261.44 |
DisclosureSEC source: 0001567619-23-001532 · doc1.xml · derivative · entry 3 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,796 shares Expires 2031-01-27 F3 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F3 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F3 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:16 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,595 | $10.50 Strike: $23.50 | $48,247.50 |
DisclosureSEC source: 0001567619-23-001532 · doc1.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,595 shares Expires 2030-07-28 F2 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F2 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F2 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:16 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerCommon Stock | 15,408 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-001532 · doc1.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 08:47 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantStock Options (Right to buy) · Derivative | 49,586 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001562180-22-005426 · primarydocument.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,586 Underlying: Common Stock · 49,586 shares Expires 2032-06-28 F2 · derivative.exercise_date: The Options vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date and (ii) the date of the 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 08:47 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantCommon Stock | 34,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005426 · primarydocument.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,682 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| May 17, 2022 Filed May 19, 2022 09:03 UTC | Sonendo, Inc. SONX · Entity 9738 | PurchaseCommon Stock | 20,000 | $2.90 | $58,000.00 |
DisclosureSEC source: 0001562180-22-004226 · primarydocument.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Read SEC document |
| May 16, 2022 Filed May 18, 2022 09:03 UTC | Sonendo, Inc. SONX · Entity 9738 | PurchaseCommon Stock | 15,000 | $2.85 | $42,750.00 |
DisclosureSEC source: 0001562180-22-004176 · primarydocument.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.69 to $2.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 13, 2022 Filed May 17, 2022 09:00 UTC | Sonendo, Inc. SONX · Entity 9738 | PurchaseCommon Stock | 15,000 | $2.67 | $40,050.00 |
DisclosureSEC source: 0001562180-22-004079 · primarydocument.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.67 to $2.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 11:34 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 5,656 | $0.00 Strike: $20.75 | $0.00 |
DisclosureSEC source: 0001127602-22-002347 · form4.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,656 Underlying: Common Stock · 5,656 shares Expires 2032-01-26 F2 · derivative.exercise_date: These options are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 25, 2023. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 11:34 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 3,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002347 · form4.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,408 F1 · shares: These restricted stock units are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 25, 2023. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 17:19 UTC | Sonendo, Inc. SONX · Entity 9738 | PurchaseCommon Stock | 16,000 | $12.00 | $192,000.00 |
DisclosureSEC source: 0000899243-21-042401 · doc4.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 12:00 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 5,796 | $0.00 Strike: $21.36 | $0.00 |
DisclosureSEC source: 0001127602-21-002937 · form4.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,796 Underlying: Common Stock · 5,796 shares Expires 2031-01-27 F2 · derivative.exercise_date: These options are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 26, 2022. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 12:00 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 1,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002937 · form4.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,396 F1 · shares: These restricted stock units are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 26, 2022. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 10:47 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 5,000 | $17.65 | $88,265.50 |
DisclosureSEC source: 0001127602-20-030093 · form4.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,851 F1 · price: Prices range from $17.5790 per share to $17.6700 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 16:36 UTC Amendment | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 5,000 | $17.99 | $89,949.50 |
DisclosureSEC source: 0001127602-20-023455 · form4a.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,851 Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 13:48 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 4,595 | $0.00 Strike: $8.71 | $0.00 |
DisclosureSEC source: 0001567619-20-013872 · doc1.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,595 Underlying: Common Stock · 4,595 shares Expires 2030-07-28 F2 · derivative.exercise_date: These options are awarded under the 2012 Stock Incentive Plan and vest 25% every 45 days from the date of the grant. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 13:48 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 851 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013872 · doc1.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest 25% every 45 days from the date of the grant. Read SEC document |
| July 28, 2020 Filed Aug 12, 2020 16:36 UTC Amendment | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 4,595 | $0.00 Strike: $23.50 | $0.00 |
DisclosureSEC source: 0001127602-20-023455 · form4a.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,595 Underlying: Common Stock · 4,595 shares Expires 2030-07-28 F1 · derivative.exercise_price: This $23.50 Exercise Price serves to correct/replace the $8.7058 that was incorrectly reflected on the original Form 4 filed July 29, 2020. F2 · derivative.exercise_date: These options awarded under the 2012 Stock Incentive Plan vest 25% every 45 days from the date of grant. Read SEC document |
| December 21, 2019 Filed Dec 26, 2019 08:49 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 968 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-024853 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968 Underlying: Common Stock · 968 shares Expires 2020-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| December 21, 2019 Filed Dec 26, 2019 08:49 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 968 | $0.11 | $106.48 |
DisclosureSEC source: 0001437749-19-024853 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| September 21, 2019 Filed Sep 23, 2019 16:27 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 968 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-018893 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936 Underlying: Common Stock · 968 shares Expires 2020-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| September 21, 2019 Filed Sep 23, 2019 16:27 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 968 | $1.53 | $1,481.04 |
DisclosureSEC source: 0001437749-19-018893 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 17:39 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 969 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-012449 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,904 Underlying: Common Stock · 969 shares Expires 2020-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 17:39 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 969 | $3.60 | $3,488.40 |
DisclosureSEC source: 0001437749-19-012449 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| May 06, 2019 Filed May 6, 2019 17:10 UTC | Nuvectra Corp NVTR · Entity 152882 | PurchaseCommon Stock | 14,000 | $6.24 | $87,360.00 |
DisclosureSEC source: 0001437749-19-008862 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,489 F1 · security: Open market purchase. Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 16:22 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 837 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-006877 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,873 Underlying: Common Stock · 837 shares Expires 2019-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 16:22 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 837 | $10.51 | $8,796.87 |
DisclosureSEC source: 0001437749-19-006877 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 16:16 UTC | Nuvectra Corp NVTR · Entity 152882 | GrantStock Option (right to buy) · Derivative | 6,455 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001437749-19-005604 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,325 Underlying: Common Stock · 6,455 shares Expires 2029-03-21 F2 · security: Grant of stock options, which vests in four equal quarterly installments beginning on June 21, 2019. F2 · derivative.exercise_date: Grant of stock options, which vests in four equal quarterly installments beginning on June 21, 2019. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 16:16 UTC | Nuvectra Corp NVTR · Entity 152882 | GrantRestricted Stock Unit · Derivative | 3,873 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-005604 · rdgdoc.xml · derivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,710 Underlying: Common Stock · 3,873 shares Expires 2020-03-21 F1 · security: Grant of restricted stock units, which vests in four equal quarterly installments beginning on June 21, 2019. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F1 · derivative.exercise_date: Grant of restricted stock units, which vests in four equal quarterly installments beginning on June 21, 2019. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:03 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 837 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-000727 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837 Underlying: Common Stock · 837 shares Expires 2019-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:03 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 837 | $15.63 | $13,082.31 |
DisclosureSEC source: 0001437749-19-000727 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 16:30 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 838 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-018184 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,674 Underlying: Common Stock · 838 shares Expires 2019-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 16:30 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 838 | $23.19 | $19,433.22 |
DisclosureSEC source: 0001437749-18-018184 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| July 09, 2018 Filed Jul 9, 2018 17:16 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 838 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-013130 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,512 Underlying: Common Stock · 838 shares Expires 2019-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| July 09, 2018 Filed Jul 9, 2018 17:16 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 838 | $17.36 | $14,547.68 |
DisclosureSEC source: 0001437749-18-013130 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| April 10, 2018 Filed Apr 11, 2018 15:45 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 837 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-006687 · rdgdoc.xml · derivative · entry 4 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 837 shares Expires 2018-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| April 10, 2018 Filed Apr 11, 2018 15:45 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 837 | $13.53 | $11,324.61 |
DisclosureSEC source: 0001437749-18-006687 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 15:45 UTC | Nuvectra Corp NVTR · Entity 152882 | GrantRestricted Stock Unit · Derivative | 3,350 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-006687 · rdgdoc.xml · derivative · entry 3 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,187 Underlying: Common Stock · 3,350 shares Expires 2019-04-09 F3 · security: Grant of restricted stock units, which vests in four equal quarterly installments beginning on July 9, 2018. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: Grant of restricted stock units, which vests in four equal quarterly installments beginning on July 9, 2018. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 15:45 UTC | Nuvectra Corp NVTR · Entity 152882 | GrantStock Option (right to buy) · Derivative | 3,350 | $0.00 Strike: $13.47 | $0.00 |
DisclosureSEC source: 0001437749-18-006687 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,870 Underlying: Common Stock · 3,350 shares Expires 2028-04-09 F2 · security: Grant of stock options, which vests in four equal quarterly installments beginning on July 9, 2018. F2 · derivative.exercise_date: Grant of stock options, which vests in four equal quarterly installments beginning on July 9, 2018. Read SEC document |
| January 10, 2018 Filed Jan 10, 2018 17:58 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionRestricted Stock Unit · Derivative | 837 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-000498 · rdgdoc.xml · derivative · entry 2 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837 Underlying: Common Stock · 837 shares Expires 2018-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
| January 10, 2018 Filed Jan 10, 2018 17:58 UTC | Nuvectra Corp NVTR · Entity 152882 | Exercise / conversionCommon Stock | 837 | $9.79 | $8,194.23 |
DisclosureSEC source: 0001437749-18-000498 · rdgdoc.xml · nonDerivative · entry 1 Bihl Anthony P III · CIK 0001432665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.